Basis Report/Resources/Investor Foundations
4 sections20 entries

Healthcare stock analysis: clinical risk, pipeline, and pricing

Healthcare analysis fails when investors apply pharmaceutical assumptions to biotech valuations or treat pipeline probability as a footnote. The right order is: classify the subsector, map the earnings drivers, then build a valuation that makes the risk explicit.

✓Write the net realized price for the company's top product — not the gross price — before you model revenue.
✓Identify which revenue streams face patent expiry in the next five years and what percentage of current EBIT they represent.
✓Classify the business as clinical-stage biotech, specialty pharma, diversified pharma, medical devices, or managed care before touching a valuation multiple.
✓For any pipeline asset driving more than 15% of the bull case, probability-weight it at realistic Phase 2-to-approval base rates — not management's preferred scenario.
Go to frameworkSee a sample report
When to use this

Use this before initiating on any clinical-stage biotech, specialty pharma, large-cap pharmaceutical, medical device, or managed care company. Start with the subsector classification — it determines which analytical framework applies and which risks deserve the most weight.

Why it matters now

The Inflation Reduction Act introduced Medicare drug price negotiation for the first time, biosimilar competition is accelerating across biologics that once seemed insulated, and elevated FDA scrutiny after a decade of accelerated approvals has compressed realistic pipeline success probabilities. Investors who can value businesses on true net realized pricing and honest pipeline probabilities have a structural edge over those anchoring on gross prices and management roadmaps.

Where theses break

The blueprint breaks when revenue models use gross price (WAC) instead of net realized price after rebates, pipeline probability is applied as a linear decimal to current earnings rather than through probability-weighted NPV, and a large total addressable market claim substitutes for demonstrated commercial execution in the relevant indication and reimbursement environment.

Full framework

4 sections · 20 entries — work through each before you size a position.

Most weak healthcare research anchors on gross drug prices that bear no resemblance to net realized revenue, treats binary clinical trial probabilities as convenient decimal multipliers, and underestimates how quickly patent cliffs erode earnings when the pipeline replacement is thin. Strong healthcare research classifies the business model first, then maps valuation to the specific risk architecture of that subsector.

20 entries in view

Classify the subsector before you frame the analysis

Healthcare investing fails most visibly when investors apply the wrong analytical lens. Biotech is a portfolio of probability-weighted bets. Pharma is an income stream facing known patent expiry dates. Devices are about procedure adoption and organic growth quality. Managed care is about pricing discipline and medical trend management. Each requires a different starting framework.

Separate clinical-stage biotech from commercial pharma before touching a multiple

Clinical-stage biotech is a probability-weighted option portfolio. The relevant valuation is rNPV — the sum of each asset's net peak sales potential, discounted for development risk, time to peak, and competitive dynamics at launch. Commercial pharma is an income stream with known patent expiry dates and pipeline replacement coverage. Applying a P/E multiple to a biotech whose value is 85% pre-clinical and Phase 2 pipeline is a category error that produces a number that cannot be stress-tested.

Why it matters

The most expensive mistake in healthcare investing is treating biotech as a discounted version of pharma. It is a different financial instrument that requires a different valuation method and a different risk tolerance framework.

When it matters

Before initiating any position in a company where clinical-stage pipeline assets represent more than 30% of the bull case value.

Investor take

Write one sentence classifying the company as primarily clinical-stage, primarily commercial, or a mix — then choose the valuation method appropriate for each layer of value before combining them into a single view.

Identify the primary earnings driver: volume, net price, enrollment, or clinical outcome

Pharma earnings are driven by net realized price and patient volume on key products. Device earnings are driven by procedure volumes and average selling price. Managed care earnings are driven by premium yield minus medical cost trend. Clinical-stage company values are driven by clinical outcomes and the NPV implications of approval. Misidentifying the primary driver leads to modeling the wrong variable with the most precision and leaving the actual value-driver underspecified.

Why it matters

Investors who model every healthcare company through a trailing earnings-per-share lens miss the cases where the earnings multiple is not the right mechanism — particularly during early commercial launches and clinical-stage development where current earnings tell you almost nothing about value.

When it matters

At the start of any new research effort, and whenever a company is transitioning between categories — for example, a biotech approaching first commercial launch.

Investor take

Map the primary earnings driver to the primary valuation variable before building any quantitative model. That mapping tells you what deserves the most sensitivity analysis and what can be held constant.

Map the patent or regulatory risk timeline before modeling beyond three years

Every commercial pharmaceutical product has a known expiry date for its primary composition-of-matter and method-of-use patents. Generic and biosimilar manufacturers file patent challenges years before loss of exclusivity, often creating earlier-than-expected competition. Device clearances can be narrowed or revoked. Managed care contracts reprice annually. These are not black swans — they are scheduled or semi-scheduled events that belong in the base case model, not in the bear case as a stress scenario.

Why it matters

Investors who ignore patent timelines in a five-year earnings model are not being optimistic — they are building a model that will predictably overstate earnings in the years the cliff arrives. The market will price the cliff before management acknowledges it in guidance.

When it matters

When building any multi-year revenue or earnings model for a company with material commercial pharmaceutical revenue.

Investor take

List every product contributing more than 10% of EBIT alongside its primary patent expiry date and the most recent generics/biosimilars pipeline data. If that list shows multiple LOE events within five years without replacement pipeline in late-stage development, model the cliff in the base case rather than extrapolating current growth through it.

Understand reimbursement architecture before modeling peak sales for any product

An FDA approval is not a reimbursement approval. Formulary access — what tier the drug lands on, what prior authorization or step therapy hurdles the insurer requires, what co-pay applies to the patient — determines actual patient volume. A drug that achieves FDA approval but lands on the third tier of a major PBM formulary with mandatory step-through requirements may reach only 40-50% of its addressable volume in the first two years. Reimbursement is a separate gatekeeping process with its own probability and timeline.

Why it matters

Multiple successful drugs have failed commercially because formulary access was restricted by PBMs who excluded the product or placed it at a tier that made patient co-pays prohibitive relative to an alternative. The FDA and the payer evaluate different things and reach independent conclusions.

When it matters

When modeling the commercial trajectory for any new product launch, particularly in therapeutic classes where a lower-cost alternative already exists and PBMs have demonstrated willingness to use formulary exclusion as a pricing lever.

Investor take

Check the formulary status of the closest comparable drug that launched in the same therapeutic area in the last five years. The time from approval to broad formulary access in that precedent is the realistic commercial ramp benchmark, not management's launch guidance.

Evaluate capital allocation discipline: internal R&D productivity versus acquisition dependence

Large pharma companies allocate capital through three channels: internal R&D, licensing and business development, and acquisitions. Companies that generate approved medicines primarily through internal discovery tend to have higher R&D return on capital because drug economics flow entirely to the owner. Companies that rely heavily on late-stage acquisitions to replace expiring revenue pay for proven assets at full value and take on execution risk on the commercial continuation. Both strategies can work — but they imply different long-run margins, different capital intensity, and different quality of earnings.

Why it matters

A pharma company spending $10B annually on R&D but generating one approved NME every three years is not compounding internal discovery — it is funding a research operation whose productivity gap is being papered over by M&A. The distinction matters because acquisitions eventually run out and the R&D base rate becomes the terminal earnings driver.

When it matters

When evaluating any large pharma or specialty pharma company with a significant patent cliff in the next five years and a pipeline that includes a high proportion of acquired or licensed assets.

Investor take

Count what percentage of late-stage pipeline by estimated value was internally generated versus acquired or in-licensed. If more than 60% is external in a company claiming a strong internal discovery engine, the research platform is less valuable than the pipeline slide implies.

Read the clinical pipeline as a probability-weighted financial event calendar

Clinical trial outcomes create the most violent single-session moves in healthcare stocks. Understanding realistic success probabilities — not management's preferred framing — and mapping them to financial value is the analytical core of healthcare investing.

Use stage-appropriate base-rate success probabilities, not management's preferred risk adjustment

Average Phase 2-to-approval success rates across all indications run approximately 10-15%. For rare disease with breakthrough designation, 30-40%. For oncology, where Phase 2 results are often less predictive of pivotal outcomes, closer to 8-12%. These are industry-level base rates. Management's probability estimates are almost always more optimistic. The discipline is to start with the base rate and adjust upward only on the basis of mechanism novelty supported by prior clinical evidence, the quality of Phase 2 data, and the unmet need level — not from the confidence level of the prepared remarks.

Why it matters

Applying a 75-80% probability to a Phase 2 asset without compelling mechanistic precedent dramatically overstates the risk-adjusted value. The market will often reprice to base-rate probability regardless of management confidence when the data release date approaches.

When it matters

When building a pipeline-asset NPV for any pre-Phase 3 asset contributing more than 15% of the bull case value.

Investor take

Build a two-column comparison: management's stated probability for each asset alongside the industry base rate for the indication and development stage. The gap between those numbers is the market's embedded probability premium — quantify it before the event forces the correction.

Model the label scenario alongside the approval probability

FDA approval does not guarantee broad indication coverage. A drug approved for second-line treatment in a narrow patient population that management modeled as first-line broad use may achieve 30-40% of the expected peak sales even with a technically successful regulatory outcome. Label risk — the scope of indication granted versus the scope assumed in the commercial model — is a frequent source of post-approval underperformance when the stock falls despite an announced approval.

Why it matters

Post-approval stock declines often reflect label narrowness rather than outright rejection. Management's commercial model almost always reflects broad label coverage; the FDA grants something more constrained. The gap between the modeled and actual patient population is the revenue miss.

When it matters

When modeling peak sales for any pipeline asset six to twelve months before the anticipated PDUFA date, using advisory committee briefing documents and comparable product label precedents in the same therapeutic area.

Investor take

Find the two most recent FDA approvals in the same indication and read the actual approved label versus the pre-approval commercial model. The label scope in comparable situations is your most reliable forecast for what the agency will and will not include.

Quantify IRA Medicare negotiation exposure by product and timeline

The Inflation Reduction Act gives Medicare authority to negotiate prices directly on high-cost drugs, beginning with small molecules nine years after first approval and biologics thirteen years after first approval. For drugs with large Medicare patient populations, negotiated prices can reduce net revenue by 20-60% beyond the current rebate level. Products approaching negotiation eligibility represent a structural net price decline that should be modeled explicitly — not embedded in a generic pricing pressure assumption.

Why it matters

The IRA's financial impact on pharmaceutical revenue is the most significant structural change to U.S. drug pricing in a generation. Companies modeling it as a 2-3% blended annual price decline are dramatically underestimating the revenue impact on qualifying products that are both large-revenue and Medicare-heavy.

When it matters

When modeling any pharmaceutical company with products that will reach Medicare price negotiation eligibility within the investment horizon — nine years post-approval for small molecules, thirteen for biologics.

Investor take

Map each major product to its approval year and calculate when it becomes eligible for negotiation. For products with large Medicare populations — often 40-70% of patients for drugs treating age-related conditions — build a negotiated price scenario using the first published round of negotiated prices as a magnitude proxy.

Track pipeline replacement coverage against the patent cliff timeline

Pipeline replacement coverage is the ratio of late-stage pipeline expected peak sales (probability-weighted) to the revenue that will be lost through patent expiry in the same period. A ratio above 1.5x indicates the company can grow through the cliff. Below 0.8x, the pipeline as constituted will not replace what is lost, and EPS will decline regardless of what the current P/E looks like. This ratio translates pipeline data directly into an earnings impact framework.

Why it matters

Pharma companies routinely present pipeline slides emphasizing the raw number of assets without framing them against the revenue at risk from the cliff. A 40-asset pipeline covering a $3B cliff is categorically different from one covering a $12B cliff.

When it matters

Annually for any large pharma with patent expirations representing more than 25% of revenue within the investment horizon, using the most recent investor day pipeline slide as the input.

Investor take

Build a five-year LOE bridge: revenue lost per year from expiring exclusivities versus probability-weighted revenue added per year from pipeline approvals. The net of those two lines is the underlying earnings trajectory before any other business variables.

Benchmark post-approval commercial launch trajectory against historical comparable launches

Year-one launch trajectories in the same indication and reimbursement environment are the most reliable benchmark for a new drug's commercial ramp. Management guidance is almost always above historical peer benchmarks because it reflects the optimistic scenario. A drug launching into a competitive class where the market leader holds 60% share should be benchmarked against launches that achieved second-place positions in similar markets — not against the market leader's original trajectory.

Why it matters

Launch trajectory misses are one of the most consistent sources of post-approval consensus estimate cuts. The market models an optimistic ramp, the drug achieves median performance, and estimates move lower for two to three years after approval.

When it matters

When building the first three years of commercial revenue for any new launch, using weekly prescription data from Symphony Health or IQVIA after the first 4-8 weeks of launch as the real-time leading indicator.

Investor take

Collect launch trajectories for the three most comparable approvals in the same indication in the last five years. Apply the median ramp as your base case and the top-quartile ramp as your bull case. Management's guidance typically sits at or above the top quartile before prescription data exists to test it.

Stress the commercial moat and reimbursement floor

Commercial healthcare moats are built on IP protection, reimbursement entrenchment, clinical differentiation, and patient switching costs. They erode on patent expiry, formulary exclusion, and the arrival of a clinically comparable lower-cost alternative. Mapping that erosion timeline is as important as mapping the upside.

Read net price trend as the true pricing power signal, not WAC

Gross price increases of 8-10% per year are visible and reported. Net price realization — after PBM rebates, mandatory government discounts, and patient support programs — is rarely disclosed but often falls even as gross prices rise. A company raising WAC 8% while conceding 12% more in rebates is reporting price increases while experiencing net price declines. The net/WAC ratio over time is the honest measure of pricing power — not the gross price increase.

Why it matters

Investors tracking only WAC changes are measuring the number that management controls most directly, not the number that determines actual revenue. Net price declines have repeatedly surprised consensus estimates on major pharmaceutical franchises that appeared to be raising prices.

When it matters

Quarterly, using management's price/volume/mix bridge in the earnings release and triangulating against prescription data to derive implied net revenue per prescription over time.

Investor take

Compare the company's stated WAC increases to the net price impact disclosed in the earnings bridge over four or more quarters. A persistent wedge — WAC rising faster than net — is erosion in pricing power that will eventually compress gross margin as the rebate stack continues to widen.

Identify biosimilar entry risk: which biologics face near-term competition and at what penetration rate

Biosimilar penetration in the U.S. has been slower than in Europe due to physician inertia, interchangeability hurdles, and originator co-pay assistance programs that reduce patients' financial incentive to switch. However, interchangeability designations — allowing pharmacists to substitute without physician authorization — have accelerated penetration where granted. Drugs with interchangeable biosimilar approvals in competitive markets have experienced 30-50% volume erosion within three years; those without interchangeability have held better, closer to 10-25% decline.

Why it matters

Biosimilar entry is the closest analogue to generic entry for biologics. The rate of penetration depends on interchangeability status, payer formulary decisions, and originator rebate willingness — each of which can be tracked before the revenue impact appears in the income statement.

When it matters

When evaluating any originator biologic with U.S. revenue above $500M that has biosimilar approvals already granted or applications pending from multiple manufacturers.

Investor take

Build a penetration model using the adalimumab (Humira) biosimilar trajectory as the high-penetration benchmark and the trastuzumab (Herceptin) experience as the mid-penetration benchmark. Identify which environment most closely matches the competitive and interchangeability profile of the product you are analyzing.

Test formulary access as a leading commercial indicator before it appears in prescription trends

Formulary tier and prior authorization requirements are set by PBMs annually and take effect at the start of each coverage year. A drug excluded from a major PBM formulary in January will see prescription volume decline in Q1 before the year-over-year revenue impact fully materializes. Formulary exclusion lists from the three major PBMs are published in advance and represent one of the clearest leading indicators of near-term prescription volume pressure available to investors.

Why it matters

Formulary exclusion of a branded drug in a competitive class typically triggers a 15-25% volume decline within two quarters because patients and physicians face active switching pressure from their insurer rather than simply having passive access to alternatives.

When it matters

In Q4 each year when PBMs publish their January formulary exclusion lists, and whenever a competitive drug launches with a meaningfully lower net price in the same therapeutic class.

Investor take

Check whether the company's key product appears on published exclusion lists from Express Scripts, CVS Caremark, and OptumRx. If excluded from any of them, estimate the impacted covered lives as a percentage of total U.S. commercial volume and build the volume impact into the base case before the Q1 earnings make it visible.

Evaluate medical device organic growth through volume and price decomposition

Device revenue growth that reports as 8% often decomposes into: procedure volume growth from market development or penetration gains, average selling price change that is frequently negative under hospital GPO pressure, and mix shift toward higher or lower-value product tiers. A business growing 8% through volume expansion in an underpenetrated market with stable pricing is a fundamentally different quality of growth than one growing 8% through pricing in a mature market with flat procedure volumes.

Why it matters

Device companies with structural volume tailwinds — robotic surgery, electrophysiology ablation, continuous glucose monitoring — can sustain high single-digit organic growth. Those in mature categories depend on pricing or market development that is less durable and often faces incremental GPO resistance.

When it matters

When evaluating any medical device company reporting mid-to-high single digit organic revenue growth and determining whether that growth rate can sustain the premium multiple in the current valuation.

Investor take

Ask management to decompose growth into volume, price, and mix explicitly. If not disclosed, triangulate from procedure volume data in Medicare claims or industry association procedure statistics against reported device revenue.

Assess managed care MLR trend by segment before accepting blended company-level results

Managed care companies report multiple business segments: commercial insurance, Medicare Advantage, Medicaid managed care, and specialty businesses. Each carries a different baseline MLR and medical trend sensitivity. A company reporting blended MLR improvement may be masking Medicare Advantage deterioration with commercial segment gains. Since Medicare Advantage is typically the fastest-growing and most closely watched segment, segment-level MLR transparency matters more than company-level blended averages.

Why it matters

Blended MLR reporting can delay the visibility of pressure building in the most critical segment by one to two quarters. By the time the company-level average deteriorates visibly, the margin problem in the highest-growth segment is often two or three quarters old.

When it matters

Every quarter when managed care companies report, using the segment operating margins and MLR disclosures in the 10-Q if not separately provided in the earnings release.

Investor take

If the company does not disclose segment MLR explicitly, derive it from the segment revenue and operating income disclosures. Track Medicare Advantage MLR quarterly against the prior year and against management guidance. A 100-150 basis point deterioration in MA MLR typically translates to 10-15% EPS downside in most managed care models.

Build a valuation that makes the risk explicit rather than averaging it away

Healthcare valuations that survive scrutiny are built on realistic net pricing, probability-weighted pipeline values, and patent cliff bridges that quantify the replacement gap. The companies worth owning at a premium are those with durable commercial earnings and pipeline that compounds through the cliff — not those where the thesis depends on a binary event that is still one data readout away.

Build rNPV using base-rate probabilities and realistic net pricing, then compare to market-implied value

A sum-of-the-parts rNPV for a pharmaceutical or biotech company requires four inputs per asset: realistic probability of approval from current stage, estimated net peak sales at realistic penetration and pricing (not WAC-based gross), years to peak from anticipated approval, and appropriate discount rate reflecting clinical and commercial risk. Once rNPV is built, compare it to the market-implied pipeline value, which is enterprise value minus net cash minus the NPV of current commercial assets. If implied pipeline value is well above rNPV at base rates, the market is pricing in above-average success probability — that spread is your downside on a clinical miss.

Why it matters

The market prices pipeline assets at management's probability estimate more often than at base rates. When base-rate rNPV is $10 per share and market-implied pipeline value is $25, the downside on a miss is not a 15% correction — it is the full reset to the base-rate value.

When it matters

Before any catalyst event involving a pipeline asset that represents more than 15% of market cap, and when initiating on any company where more than 40% of enterprise value is attributable to clinical-stage assets.

Investor take

Calculate the implied pipeline value as (enterprise value minus commercial earnings NPV minus net cash). Compare that to your base-rate rNPV. The difference is the embedded probability premium — write it down and decide whether the position is sized appropriately for that gap before the data arrives.

Model the patent cliff bridge explicitly: revenue lost versus revenue added, year by year

The most useful output of a pharma valuation is not a DCF terminal value but a bridge showing revenue lost per year from loss of exclusivity versus revenue added from pipeline approvals, year by year for the next five years. That bridge tells you whether EPS grows or contracts, when the trough occurs, and whether the pipeline replacement runway is sufficient to sustain the current capital return program. A company with a $6B LOE in year three and $4B of probable pipeline launches between year two and year four has a priceable one-year earnings trough — it should be in the model, not the bear case.

Why it matters

Investors who rely on a single DCF terminal value to value pharma through a patent cliff often understate the trough year severity because the model smooths what is a discrete revenue step-down. The bridge forces the trough to be visible before the stock prices it.

When it matters

When analyzing any large-cap pharmaceutical company with one or more blockbusters losing exclusivity within the investment horizon.

Investor take

Build a product-level revenue bridge: current revenue by major product, expected year of LOE, approximate revenue erosion using 75% for small molecules in 18 months and 35% for biologics in two years, and probability-weighted launch year and peak sales for each material pipeline asset.

Normalize earnings for recurring items that management consistently excludes from adjusted EPS

Pharmaceutical adjusted EPS often excludes amortization of acquired intangibles, restructuring charges, litigation settlements, and milestone payments. These exclusions are not equivalent. Amortization of acquired intangibles is a real economic cost representing the premium paid for drugs the company is now selling commercially. Recurring restructuring charges are an ongoing cost of doing business in a sector that regularly reorganizes its commercial and research infrastructure. Accepting management's adjusted figure without scrutiny systematically overstates sustainable earnings power.

Why it matters

Biotech and specialty pharma companies acquired for pipeline pay intangible asset premiums that amortize over the product life. Excluding that amortization from the adjusted earnings makes the P/E multiple look lower than it actually is relative to a company that grew its drugs organically without acquisition premiums.

When it matters

When comparing P/E or EV/EBITDA across pharmaceutical companies with different acquisition histories, and when evaluating whether a company's adjusted EPS figure represents sustainable cash generation or a managed presentation.

Investor take

Build your own normalized earnings by retaining only the amortization of intangibles that will fully expire within the model period and removing recurring restructuring charges. Compare normalized EPS to GAAP EPS and management adjusted EPS. The three-number comparison shows what is genuinely one-time versus structurally recurring.

Size the downside before the catalyst, not after

Healthcare binary events — Phase 3 readouts, FDA PDUFA decisions, CMS reimbursement determinations — move stocks 20-60% in a single session. The analytical decision is not which way the outcome goes; it is whether the current risk/reward justifies holding through the event. That requires knowing the implied probability embedded in the current stock price, the upside if the event is positive, and the downside if it is negative. All three numbers should be written before the event date — not reconstructed afterward to explain the move.

Why it matters

Most investors who lose significant capital in healthcare binary events held too much exposure because they never explicitly calculated the downside scenario. The stock looked cheap against the bull case, until it moved to the bear case and looked even cheaper at a lower price.

When it matters

Before every scheduled binary event for any position where the outcome could move the stock more than 10% in either direction.

Investor take

Calculate the downside scenario by stripping out the probability-weighted pipeline value for the asset at risk and replacing it with the rNPV at zero probability of approval. The difference between the current stock price and that floor is the maximum loss scenario. Decide whether position sizing is appropriate for that number before the event.

Apply the right multiple to each layer of value in a sum-of-the-parts healthcare model

Healthcare companies often have distinct value layers that deserve different multiples: a current commercial franchise (value as a durable income stream; apply an earnings or FCF multiple), near-term pipeline at high probability (value using DCF or EV/peak sales at near-launch probabilities), early-stage pipeline (apply option value with realistic stage probability), and net cash. Blending these into a single earnings multiple produces a misleading valuation — particularly when early-stage pipeline is material, because that pipeline does not belong in the earnings base that the multiple is applied to.

Why it matters

Applying 15x P/E to blended earnings with zero pipeline contribution and then adding a subjective pipeline optionality premium is not a valuation. It is a range of numbers that can justify any conclusion the analyst wants to reach.

When it matters

When building an initiating model for any pharmaceutical company with material clinical-stage pipeline and when revisiting a thesis after a large pipeline-driven stock move.

Investor take

Segment the valuation explicitly: commercial earnings NPV, rNPV on late-stage pipeline, option value on early-stage pipeline, and net cash. Sum the components and compare to market cap. That comparison reveals what the market is implying about each layer and whether any layer is priced at assumptions you disagree with.

Evidence

Healthcare metrics scorecard

The metrics that reveal earnings quality before the catalyst or patent cliff arrives

These metrics vary by subsector. Know which apply to the specific business you are analyzing — a managed care metric on a biotech tells you nothing useful.

Net Realized Price (Net/WAC Ratio)
Net Revenue ÷ (Units × WAC)
The ratio of actual net revenue per unit to gross list price. Most branded drugs realize 40-65% of WAC after PBM rebates, government mandated discounts, and patient support programs. A declining net/WAC ratio signals pricing erosion before the income statement fully reflects it — track it quarterly using management's price/volume/mix bridge.
Pipeline rNPV Coverage
Risk-adj. NPV of pipeline ÷ Market cap
For pre-commercial biotechs, this ratio measures how much of market cap is explained by probability-weighted pipeline value versus net cash. If the ratio is below 1.0 and the company is primarily pipeline, the market is pricing in a failure scenario or the pipeline is genuinely worth less than the stock implies. Above 1.5x suggests the market is assigning probability assumptions more optimistic than base rates support.
Patent Cliff Exposure
Revenue at LOE risk in 5 yrs ÷ Total EBIT
The share of current operating profit coming from products that will lose market exclusivity in the next five years. Above 40% without credible late-stage pipeline replacement is a structural EPS compression signal, not a temporary headwind to wait through.
Medical Loss Ratio (MLR)
Medical Costs ÷ Premium Revenue
The core managed care efficiency metric. Sustainable range is 84-86% for commercial; Medicare Advantage runs 87-91% but with more government reimbursement stability. Track the quarterly direction and compare by segment — a blended improvement that hides Medicare Advantage deterioration is one of the most common managed care earnings quality issues.
Device Organic Revenue Growth
Volume × Price; ex-M&A and FX
Medical device organic growth decomposes into procedure volume growth and average selling price change. Sustained organic growth above 7-8% usually requires volume expansion from new procedures or clinical adoption of higher-value technology. Growth driven entirely by pricing in a GPO-dominated hospital market is not durable.
R&D Productivity
NME approvals per $B of R&D spent
A long-run efficiency metric distinguishing companies that generate novel medicines from internal research versus those supplementing internal gaps with M&A. Productivity declining while R&D spend rises signals that internal discovery is becoming less efficient — watch for business development acceleration as the alternative strategy gaining share of capital allocation.

Subsector valuation map

Healthcare is not one sector — the valuation discipline must match the business model

Applying a pharma earnings multiple to a clinical-stage biotech is the most common healthcare valuation error. Classify first, then choose the analytical lens.

Healthcare is not one sector — the valuation discipline must match the business model
SubsectorPrimary valuation lensKey metrics to anchorMost common mistake
Clinical-stage BiotechSum-of-parts rNPV + net cashStage-appropriate approval probabilities, peak net sales by asset, competitive landscape at launchUsing management's optimistic peak sales as the base case and applying an 80% probability — instead of realistic net pricing at base-rate success probabilities from the current stage.
Specialty / Large PharmaP/E or EV/EBITDA on normalized net-price revenueNet realized price trend, patent cliff timing, pipeline replacement coverage vs. LOE revenueModeling revenue at gross price (WAC) without the rebate stack — a 35-40 point gap between WAC and net price makes the revenue and earnings look 20-30% too high before the mismatch corrects.
Medical DevicesEV/Sales or EV/EBIT on organic growth premiumOrganic revenue growth (volume + price), gross margin trajectory, procedure penetration rateTreating M&A-driven revenue as organic compounder quality. Acquisitions reset the organic baseline — strip them out before assigning a premium multiple on growth that is not repeatable from operations.
Managed CareP/E or EV/EBITDA on normalized MLRMLR by segment, premium yield growth, government reimbursement rate updatesExtrapolating a favorable MLR year as a permanent earnings level without accounting for medical trend acceleration into the next annual repricing cycle.

Most common mistake

Modeling drug revenue at WAC is not a conservative assumption — it is a category error

Gross price (WAC) and net realized price in U.S. pharmaceuticals are separated by a rebate stack that includes PBM base rebates, performance rebates, government mandated Medicaid best price and 340B pricing, co-pay assistance programs, and increasingly, IRA negotiated prices for Medicare beneficiaries. For many branded drugs in competitive therapeutic classes, the gap between WAC and net revenue is 35-55 cents on every dollar. A revenue model built on WAC and then discounted 10-15% for 'channel adjustments' is still systematically too high. The correct approach is to derive the net realized price — management often discloses net price impact in the earnings bridge, or it can be triangulated from segment revenue and prescription volume data — and build the model from net from the start.

Common questions

What investors ask about investor foundations for investor foundations stocks.

What is the most important metric for analyzing a pharmaceutical or biotech stock?
Net realized price on the key commercial product, expressed as a ratio to gross price (WAC). Most branded drugs in the U.S. realize 40-65% of their list price after PBM rebates, Medicaid best price provisions, patient assistance, and increasingly, IRA negotiated prices for Medicare. A drug with a $10,000 annual WAC may generate $5,000-$6,500 in actual net revenue per patient. Revenue models anchored on gross price systematically overstate the revenue line. For pre-commercial biotechs, the equivalent metric is the probability-weighted NPV of each pipeline asset using stage-appropriate success rates, not management's preferred probability.
How do you value a biotech with no current revenue?
Risk-adjusted NPV (rNPV) of the pipeline, summed across assets and added to net cash. The key inputs per asset are: probability of regulatory approval from the current stage (roughly 10-15% from Phase 2 for most oncology indications; 25-40% for rare disease with breakthrough designation), estimated net peak sales at realistic penetration and pricing, years to peak from anticipated approval, and appropriate discount rate for the clinical and commercial risk. The most common error is using management's optimistic peak sales as the base case and then multiplying by a high probability estimate. The correct approach is to build realistic net peak sales first, then apply the stage-appropriate base rate probability to the full NPV — not just to the portion management highlights.
What is a patent cliff and how does it affect a pharma company's earnings?
A patent cliff is when a branded drug loses market exclusivity and generic or biosimilar competition enters. Small-molecule generics typically erode branded revenue 70-90% within 18 months of loss of exclusivity. Biosimilars erode biologics more slowly — often 20-50% over two to three years — because interchangeability status, physician inertia, and originator rebate programs slow switching. For large pharma with concentrated revenue, the cliff timing versus pipeline replacement coverage determines whether EPS grows or contracts. A company with $8B of revenue approaching loss of exclusivity and $5B of probable late-stage pipeline launches is in an earnings trough regardless of how the current P/E looks.
What does the medical loss ratio tell you about a managed care company?
MLR — medical costs divided by premium revenue — is the core profitability metric for managed care. A sustainable commercial MLR runs 84-86%. Above 88-89%, medical trend has outrun pricing and margins are compressing. Below 82%, the company may be over-earning and faces regulatory rebate requirements or competitive repricing pressure. The direction and cause matter more than the absolute level: MLR rising from utilization acceleration is different from MLR rising from adverse enrollment mix or pricing mistakes. Trend-driven pressure is partly self-correcting through next-year premium repricing; structural mix problems require business model changes to fix.

Continue research

Keep building the foundation

How to Value a Stock Without Fooling YourselfInvestor FoundationsDCF Analysis Guide for Investors — How to Build a DCF ModelInvestor FoundationsEarnings Quality Checklist: Judge the Quarter, Not the HeadlineInvestor FoundationsCapital allocation playbook for investorsInvestor FoundationsHow to analyze a stock: first pass to convictionInvestor FoundationsReturn on invested capital: how to use ROIC without kidding yourselfInvestor Foundations

Put it on a live stock

LLY stock overviewJump to the live ticker page and report flowABBV stock overviewJump to the live ticker page and report flowUNH stock overviewJump to the live ticker page and report flowMDT stock overviewJump to the live ticker page and report flowAMGN stock overviewJump to the live ticker page and report flow